GW Pharmaceuticals PLC (NASDAQ:GWPH) had its price objective lowered by Bank of America Corporation from $160.00 to $158.00 in a research report report published on Tuesday morning. Bank of America Corporation currently has a buy rating on the biopharmaceutical company’s stock.

GWPH has been the topic of several other research reports. The Goldman Sachs Group, Inc. reaffirmed a neutral rating and set a $124.00 target price on shares of GW Pharmaceuticals PLC in a research report on Friday, October 6th. Zacks Investment Research cut GW Pharmaceuticals PLC from a buy rating to a hold rating in a research report on Monday, July 24th. Maxim Group set a $135.00 price objective on GW Pharmaceuticals PLC and gave the stock a buy rating in a research report on Monday, August 7th. Cantor Fitzgerald set a $208.00 price objective on GW Pharmaceuticals PLC and gave the stock a buy rating in a research report on Tuesday, August 8th. Finally, Evercore ISI started coverage on GW Pharmaceuticals PLC in a research report on Wednesday, August 16th. They issued an outperform rating and a $154.00 price objective for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of Buy and an average price target of $144.55.

Shares of GW Pharmaceuticals PLC (NASDAQ GWPH) opened at $115.88 on Tuesday. The company has a quick ratio of 10.26, a current ratio of 10.39 and a debt-to-equity ratio of 0.02. GW Pharmaceuticals PLC has a 52-week low of $92.65 and a 52-week high of $136.95.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/18/bank-of-america-corporation-lowers-gw-pharmaceuticals-plc-gwph-price-target-to-158-00.html.

A number of hedge funds have recently modified their holdings of the stock. Royal Bank of Canada raised its stake in GW Pharmaceuticals PLC by 0.4% in the 2nd quarter. Royal Bank of Canada now owns 4,240 shares of the biopharmaceutical company’s stock worth $424,000 after acquiring an additional 18 shares during the last quarter. Creative Planning raised its stake in GW Pharmaceuticals PLC by 1.4% in the 2nd quarter. Creative Planning now owns 2,532 shares of the biopharmaceutical company’s stock worth $254,000 after acquiring an additional 35 shares during the last quarter. IHT Wealth Management LLC raised its stake in GW Pharmaceuticals PLC by 18.0% in the 2nd quarter. IHT Wealth Management LLC now owns 656 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 100 shares during the last quarter. Advisor Group Inc. raised its stake in GW Pharmaceuticals PLC by 10.7% in the 2nd quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 145 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its stake in GW Pharmaceuticals PLC by 8.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,064 shares of the biopharmaceutical company’s stock worth $207,000 after acquiring an additional 162 shares during the last quarter. Institutional investors own 75.71% of the company’s stock.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Stock Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.